Can you ask if anyone figured out how to make NA-931 yet? The tradename is "Bioglutide".

Thanks for the pictures. Fascinating stuff!
 
Yeah good call. When do you think it will be public? I wonder if the UGL stuff will be injectable not oral because it seems like the drug delivery system would be quite complicated to mimick.
Tough to say for certain. If it's as exceptional as they advertise they will do anything and everything to prevent it from being public. It usually comes out in patent filings but companies use methods to delay it beyond that.

The IGF-1 receptor activation for a non-peptide small molecule is quite novel, and the moment it is public many companies will create structurally similar compounds to compete.

Depending on how Biomed proceeds, it could be public anytime from now until actual approval, likely in a few years at the latest.
 
Tough to say for certain. If it's as exceptional as they advertise they will do anything and everything to prevent it from being public. It usually comes out in patent filings but companies use methods to delay it beyond that.

The IGF-1 receptor activation for a non-peptide small molecule is quite novel, and the moment it is public many companies will create structurally similar compounds to compete.

Depending on how Biomed proceeds, it could be public anytime from now until actual approval, likely in a few years at the latest.
I don't know if this was a language model hallucination or something from the actual research but is the compound a metabolite of igf1 with cross receptor activation of GLP1?

If they figured out a way to avoid triggering hypertrophy in cardiomyocytes it would be a huge deal.
 
I don't know if this was a language model hallucination or something from the actual research but is the compound a metabolite of igf1 with cross receptor activation of GLP1?

If they figured out a way to avoid triggering hypertrophy in cardiomyocytes it would be a huge deal.
Apparently so, you'd be right to be skeptical. Additionally, it's being combined with tirzepatide in trials which sounds quite redundant if it had relevant agonism to glp-1/gip.

By the time it is approved, assuming it doesn't fail trials, I imagine it won't be that revolutionary if we have myostatin inhibitors approved for weight loss, as they'd be widely available without reliance on China. Similar to how Repatha (evolocumab) is available through Indian pharma.
 
Back
Top